

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Ceritinib for previously treated anaplastic lymphoma kinase-positive non-small-cell lung cancer**

**Batch 36**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

It was noted during consultation that crizotinib is not recommended by NICE, but is available in England through the Cancer Drugs Fund (CDF). Because the CDF does not fund treatments in Wales, the comment suggested that including comparators that are available through the CDF would not reflect clinical practice in Wales.

Scoping workshop attendees noted that crizotinib is not routinely available on the NHS. They considered that if the licence for ceritinib requires previous crizotinib use, this could restrict access to ceritinib, which they considered to be a targeted therapy offering potential benefits to people with a rare type of non-small-cell lung cancer.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Neither of the potential equality issues above are likely to need addressing by the Committee.

As of April 2013, NICE issues guidance for England only, and so the comparators in the scope do not need to reflect clinical practice in Wales.

In its appraisals of health technologies, NICE is bound by the licensed

indication of the technology under appraisal. If the licence for ceritinib requires previous crizotinib use, NICE will have to appraise ceritinib, with its licensed indication, given the funding circumstances for crizotinib.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No, there were no changes to the draft scope to highlight potential equality issues.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders related to potential equality issues have been identified during the scoping process.

**Approved by Associate Director (name):** Helen Knight

**Date:** March 2015